STOCK TITAN

MapLight (NASDAQ: MPLT) counsel sells 1,827 shares mainly to cover taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics General Counsel Kristopher Hanson reported small open‑market sales of Voting Common Stock primarily to cover taxes on vesting stock awards. He sold a total of 1,827 shares across three transactions at prices around $26.80, $27.01, and $27.49 per share, as described with weighted average price ranges in the footnotes.

A footnote states the transactions represent shares sold to satisfy statutory tax withholding obligations tied to restricted stock unit vesting, indicating these are mechanistic rather than discretionary sales. After these transactions and prior plan purchases, Hanson directly holds 190,165 shares of MapLight Therapeutics common stock.

Positive

  • None.

Negative

  • None.
Insider Hanson Kristopher
Role General Counsel
Sold 1,827 shs ($49K)
Type Security Shares Price Value
Sale Voting Common Stock 73 $27.01 $2K
Sale Voting Common Stock 225 $27.49 $6K
Sale Voting Common Stock 1,529 $26.80 $41K
Holdings After Transaction: Voting Common Stock — 190,390 shares (Direct)
Footnotes (1)
  1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5). Includes 410 shares acquired under the Issuer's stock purchase plan on March 31, 2026. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive.
Total shares sold 1,827 shares Voting Common Stock sales reported in Form 4
Sale price 1 $26.80 per share 1,529 shares of Voting Common Stock sold
Sale price 2 $27.01 per share 73 shares of Voting Common Stock sold
Sale price 3 $27.49 per share 225 shares of Voting Common Stock sold
Shares held after transactions 190,165 shares Direct ownership of Voting Common Stock after sales
Plan shares acquired 410 shares Acquired under stock purchase plan on March 31, 2026
Price range example $26.33–$27.29 Weighted average sale price range noted in footnote
restricted stock units financial
"in connection with the vesting of the restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
statutory tax withholding obligations financial
"shares required to be sold to cover the statutory tax withholding obligations"
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock purchase plan financial
"Includes 410 shares acquired under the Issuer's stock purchase plan"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hanson Kristopher

(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CALIFORNIA 94063

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock04/15/2026S1,529(1)D$26.8(2)190,463(3)D
Voting Common Stock04/16/2026S73(1)D$27.01(4)190,390D
Voting Common Stock04/16/2026S225(1)D$27.49(5)190,165D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5).
3. Includes 410 shares acquired under the Issuer's stock purchase plan on March 31, 2026.
4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive.
/s/ Kristopher L. Hanson04/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MapLight Therapeutics (MPLT) General Counsel Kristopher Hanson report in this Form 4?

Kristopher Hanson reported selling 1,827 shares of MapLight Therapeutics Voting Common Stock. The filing explains these sales were made mainly to cover statutory tax withholding obligations from restricted stock unit vesting, rather than as large discretionary trades, and he continues to hold 190,165 shares.

How many MapLight Therapeutics (MPLT) shares did Kristopher Hanson sell and at what prices?

Hanson sold 1,827 shares of Voting Common Stock in three transactions. Reported prices include $26.80, $27.01, and $27.49 per share, with footnotes noting weighted average prices from ranges between about $26.22 and $27.99 across multiple trade executions.

Why were Kristopher Hanson’s MapLight Therapeutics (MPLT) shares sold according to the Form 4 footnotes?

The Form 4 footnotes state the reported sales represent shares required to be sold to cover statutory tax withholding obligations. These obligations arose in connection with the vesting of restricted stock units, indicating the transactions are tax-related rather than purely discretionary portfolio sales.

How many MapLight Therapeutics (MPLT) shares does Kristopher Hanson own after these transactions?

After the reported sales, Hanson directly holds 190,165 shares of MapLight Therapeutics Voting Common Stock. This remaining stake, as shown in the post-transaction share figures, indicates the 1,827 shares sold represent a small portion of his overall ownership position.

What do the weighted average price footnotes mean in the MapLight Therapeutics (MPLT) Form 4?

The footnotes explain that reported prices are weighted averages across multiple trades in specified ranges. For example, some shares were sold between about $26.33 and $27.29. Hanson undertakes to provide detailed trade-by-trade pricing information upon request to investors or regulators.

Did Kristopher Hanson acquire any MapLight Therapeutics (MPLT) shares recently under a stock purchase plan?

Yes. A footnote states his holdings include 410 shares acquired under MapLight Therapeutics’ stock purchase plan on March 31, 2026. This purchase plan participation adds to his long-term ownership alongside the compensation-related restricted stock units referenced in the filing.